STOCK TITAN

DNTH insider sells 27,594 shares via 10b5-1; plans 1,198-share option sale (DNTH)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Insider notice of planned sale and recent 10b5-1 disposals. The filing reports 1,198 shares of Common Stock to be sold on 03/31/2026 following an exercise of stock options for cash. It also discloses 10b5-1 sales completed on 03/24/2026 totaling 27,594 shares for $2,153,579.25.

Positive

  • None.

Negative

  • None.

Insights

Form 144 shows a scheduled exercise-related sale plus recent 10b5-1 transactions.

The notice lists an exercise of stock options that results in 1,198 shares being sold for cash on 03/31/2026. Separate line-item disclosure records 10b5-1 sales by Paula C Soteropoulos on 03/24/2026 of 27,594 shares totaling $2,153,579.25.

These entries are routine compliance filings documenting planned and recent insider dispositions under an established trading plan; cash-flow treatment for the exercise is listed as cash. Subsequent filings may show settlement or any additional dispositions.

Planned sale (exercise) 1,198 shares to be sold on 03/31/2026 following exercise of stock options
10b5-1 sale (recent) 27,594 shares sold on 03/24/2026 under a 10b5-1 plan
Proceeds reported $2,153,579.25 aggregate proceeds from 10b5-1 sales on 03/24/2026
10b5-1 regulatory
"10b5-1 Sales for PAULA C SOTEROPOULOS 7 Times Square"
A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.
exercise of stock options financial
"Securities To Be Sold | Exercise of Stock Options"
Form 144 regulatory
"Filer Information | 144: Filer Information"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the DNTH Form 144 disclose about planned sales?

The Form 144 discloses a planned sale of 1,198 shares of common stock via an exercise of stock options to be sold for cash on 03/31/2026. This is a notice of a proposed transaction under Section 16(b).

How many shares were sold under 10b5-1 prior to the DNTH filing?

The filing reports 27,594 shares sold under a 10b5-1 plan on 03/24/2026. The reported aggregate proceeds from those sales were $2,153,579.25.

Who is the reporting person in the DNTH Form 144?

The 10b5-1 sales are attributed to Paula C Soteropoulos, with an address listed at 7 Times Square, 43rd Floor, New York, NY. The filing lists that individual as the seller for the March transactions.

What proceeds were reported for the March 24, 2026 10b5-1 sale?

The filing reports aggregate proceeds of $2,153,579.25 for the 27,594 shares sold under the 10b5-1 plan on 03/24/2026. No allocation of proceeds is specified beyond the aggregate amount.